补充法律意见书（一） 上海市锦天城律师事务所 关于宁波华翔电子股份有限公司 向特定对象发行股票的 地址：上海市浦东新区银城中路 501 号上海中心大厦 11/12 层 电话：021-20511000 传真：021-20511999 邮编：200120 | | | 上海市锦天城律师事务所 补充法律意见书（一） 向特定对象发行股票的 补充法律意见书（一） 案号：01F20254132 致：宁波华翔电子股份有限公司 上海市锦天城律师事务所（以下简称"本所"）接受宁波华翔电子股份有限 公司（以下简称"宁波华翔""发行人"或"公司"）的委托，作为宁波华翔 2025 年度向特定对象发行股票相关事项（以下简称"本次向特定对象发行"） 的专项法律顾问。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中 华人民共和国证券法》（以下简称"《证券法》"）、《上市公司证券发行注册 管理办法》（以下简称"《注册管理办法》"）《深圳证券交易所股票上市规则 （2025 年修订）》等有关法律、法规、规章及规范性文件的规定，于 2025 年 9 月 29 日出具《上海市锦天城律师事务所关于宁波华翔电子股份有限公司向特定 对 ...

董事会公告 股票代码：002048 股票简称：宁波华翔 公告编号：2025-080 宁波华翔电子股份有限公司 关于向特定对象发行股票审核问询函回复 董事会 2025年11月27日 1 及募集说明书等申请文件更新的提示性公告 本公司全体董事、监事、高级管理人员保证公告内容真实、准确和完整，并对公 告中的虚假记载、误导性陈述或者重大遗漏承担责任。 宁波华翔电子股份有限公司（以下简称"公司"）于 2025 年 11 月 6 日收到深圳 证券交易所（以下简称"深交所"）下发的《关于宁波华翔电子股份有限公司申请向 特定对象发行股票的审核问询函》（审核函〔2025〕120047 号）（以下简称"《问询函》"）， 公司已会同相关中介机构进行了认真研究和落实，按照《问询函》的要求对所涉及的 事项进行了资料补充和问题回复，并对募集说明书等申请文件涉及的相关内容进行了 修订。具体内容详见公司同日在巨潮资讯网（www.cninfo.com.cn）披露的相关公告 文件。 公司本次向特定对象发行股票事项尚需通过深交所审核，并获得中国证券监督管 理委员会（以下简称"中国证监会"）作出同意注册的决定后方可实施。本次向特定 对象发行股票事项 ...

目 录 | 关于募投项目…………………………………………………第 一、 | 1—63 | 页 | | --- | --- | --- | | 二、关于经营情况……………………………………………… 第 | 63—92 | 页 | | 三、关于股权出售和关联交易…………………………………第 | 92—107 | 页 | 关于宁波华翔电子股份有限公司向特定对象 发行股票审核问询函中有关财务事项的说明 天健函〔2025〕1321 号 深圳证券交易所： 由宁波华翔电子股份有限公司转来的《关于宁波华翔电子股份有限公司申请 向特定对象发行股票的审核问询函》（审核函〔2025〕120047 号，以下简称审 核问询函）奉悉。我们已对审核问询函所提及的宁波华翔电子股份有限公司（以 下简称宁波华翔公司或公司）财务事项进行了审慎核查，现汇报如下。 一、关于募投项目 申报材料显示，本次拟向特定对象募集资金不超过 29.21 亿元，用于芜湖汽 车零部件智能制造项目（以下简称芜湖项目）、重庆汽车内饰件生产基地建设项 目（以下简称重庆项目）、研发中心建设项目（以下简称研发中心项目）、数字 化升级改造项目（以下简称数字化项目）及补充流动资金项 ...

Core Viewpoint - Ningbo Huaxiang announced its subsidiary, Ningbo Huaxiang Qiyuan Technology Co., Ltd., will invest 5 million yuan in Shanghai Lingzhi New Venture Capital Partnership, focusing on the embodied intelligence industry chain [2] Investment Details - The fund managed by Zhuhai Hillhouse Private Equity Fund Management Co., Ltd. will primarily invest in innovative companies related to the embodied intelligence industry chain [2] - The total committed capital for the partnership is targeted at 200 million yuan, with a maximum of 250 million yuan [2] Investment Focus - The fund will engage in direct or indirect equity investments, quasi-equity investments, and related activities in areas such as key raw materials and components (e.g., servo systems, motors, controllers, reducers, sensors), critical software systems, AI algorithms, and downstream application solutions in robotics [2] - The investment direction aligns with the company's ongoing efforts to explore emerging business areas, enhancing its capabilities in project collection, evaluation, and investment in this field [2]

Core Viewpoint - The collaboration between Hillhouse Capital and Zhiyuan Robotics to establish an early-stage venture capital fund, Lingzhi New Venture, aims to accelerate the development of the embodied intelligence industry by investing in innovative companies within the supply chain [1][2]. Group 1: Fund Structure and Investment Strategy - Lingzhi New Venture will primarily invest in the embodied intelligence industry, focusing on upstream key materials and components, critical software systems, and downstream application solutions [2]. - The fund has a 10-year operational period, with the first 5 years designated for investment, and can extend the period twice for one year each [2]. - The limited partners (LPs) include Longqi Technology, Ningbo Yunsheng, and Ningbo Huaxiang, with respective contributions of 30 million, 20 million, and 5 million yuan, accounting for 23.08%, 15.38%, and 3.85% of the total contributions [2][3]. Group 2: Industry Context and Company Positioning - Zhiyuan Robotics is leveraging its financial strength and strategic partnerships to invest early in the supply chain, aiming to foster growth among suppliers and enhance the overall ecosystem [1][4]. - The company has a robust cash reserve, sufficient to sustain operations for three years without revenue, supported by investments from major corporations like Tencent and LG Electronics [5]. - Zhiyuan Robotics has successfully incubated 15 early-stage projects, achieving an annualized return of 800% on investments, with a focus on seed and angel rounds [5][6]. Group 3: Strategic Partnerships and Collaborations - The three listed companies involved have existing collaborations with Zhiyuan Robotics, indicating a strategic alignment in the development of embodied intelligence applications [3]. - The partnership with Longqi Technology includes a significant order for nearly a thousand robots, showcasing the practical application of their collaboration [3].

证券日报网讯 11月24日晚间，宁波华翔发布公告称，2025年11月24日，公司下属子公司宁波华翔启源 科技有限公司（简称"华翔启源"）拟参与投资上海瓴智新创创业投资合伙企业（有限合伙）（简称"基 金""合伙企业"），其中华翔启源作为有限合伙人认缴出资500万元人民币。该基金的管理人为珠海高瓴 私募基金管理有限公司，该基金将主要围绕具身智能产业链相关的创新企业进行投资。本次交易无需提 交董事会、股东会审议通过。 （文章来源：证券日报） ...

Group 1 - Huafeng Co., Ltd. announced a stock suspension due to a potential change in control after signing a share transfer intention agreement [1] - Keshida plans to reduce its shareholding by up to 424,000 shares, representing 0.07% of its total share capital [1] - Jinqilin intends to distribute a cash dividend of 0.10 yuan per share, totaling 19.61 million yuan [1] Group 2 - Rejingshi Biotech has repurchased 904,100 shares, accounting for 0.98% of its total share capital, with a total expenditure of 150 million yuan [2] - Yishitong has repurchased 1,236,500 shares, representing 0.619% of its total share capital, with a total expenditure of approximately 33.49 million yuan [2] Group 3 - Hanjia Design announced the release of a detention on its subsidiary's chairman, allowing him to resume duties [4] - Qingmu Technology plans to acquire 65.83% of Vitalis Pharma AS for 300 million Norwegian Krone (approximately 212 million yuan) [4] - Anda Intelligent's shareholder plans to reduce its stake by up to 2.74% [4] Group 4 - Wansheng Intelligent is a candidate for a project with a pre-bid amount of approximately 42.99 million yuan, representing 4.56% of its audited revenue for 2024 [4] - Yipin Hong received a drug registration certificate for a medication used to treat Alzheimer's symptoms [4] Group 5 - *ST Sansheng received a total of 254 million yuan from restructuring investors [4] - Haichuang Pharmaceutical received approval for clinical trials of HP518 tablets for advanced prostate cancer treatment [4] Group 6 - Ningbo Huaxiang's subsidiary plans to invest 5 million yuan in a venture capital fund focusing on intelligent industries [4] - Petty Co. plans to repurchase shares worth 50 to 70 million yuan [4] Group 7 - Tongji Technology's subsidiary won a construction project with a bid price of 866 million yuan [4] - Prolo Pharmaceutical received a drug registration certificate for a generic drug [4] Group 8 - Jingyan Technology plans to use up to 1.6 billion yuan of idle funds for financial management [4] - Furan De received government subsidies totaling 34.65 million yuan [4] Group 9 - David Medical's subsidiary's medical device registration has been accepted [4] - Jusaylong plans to increase its subsidiary's capital by 170 million yuan through debt-to-equity conversion [4] Group 10 - Heng Rui Pharmaceutical's application for a drug license has been accepted by the National Medical Products Administration [4] - Lege Co. plans to increase its stake in the company by 40 to 80 million yuan [4] Group 11 - New Beiyang's subsidiary won a project with the Bank of Communications [4] - Jiangxi Changyun plans to publicly transfer land use rights and buildings with a starting price of 7.79 million yuan [4] Group 12 - Shenqi Pharmaceutical's subsidiary has paid approximately 16.67 million yuan in tax and penalties [4] - Panjiang Co. plans to invest 1.334 billion yuan in a power plant project [4] Group 13 - Fashilong's vice president resigned for personal reasons [4] - Chunxue Food received government subsidies of 3.79 million yuan [4] Group 14 - China Galaxy completed the repayment of a short-term financing bond totaling 3.025 billion yuan [4] - Jiuzhou Pharmaceutical received approval for a chemical raw material drug [4] Group 15 - Longqi Technology's subsidiary plans to invest 30 million yuan in a venture capital fund [4]

Group 1 - The company Ningbo Huaxiang announced that its subsidiary Huaxiang Qiyuan plans to invest 5 million RMB as a limited partner in the Shanghai Lingzhi New Venture Capital Partnership (Limited Partnership) [1] - The fund will be managed by Zhuhai Hillhouse Private Equity Fund Management Co., Ltd. [1] - The investment focus will be on innovative enterprises related to the embodied intelligence industry chain [1]

宁波华翔公告，公司下属子公司华翔启源拟参与投资上海瓴智新创创业投资合伙企业（有限合伙），其 中华翔启源作为有限合伙人认缴出资500万元。该基金的管理人为珠海高瓴私募基金管理有限公司，该 基金将主要围绕具身智能产业链相关的创新企业进行投资。 ...

【宁波华翔：子公司拟参与投资具身智能产业链相关创业投资基金 基金其他投资人包括智元机器人 等】智通财经11月24日电，宁波华翔(002048.SZ)公告称，公司下属子公司宁波华翔启源科技有限公司 拟参与投资上海瓴智新创创业投资合伙企业（有限合伙），认缴出资500万元。该基金主要围绕具身智 能产业链相关的创新企业进行投资，基金规模为13,000万元。基金其他认缴投资人包括智元创新（上 海）科技股份有限公司、龙旗科技等。 转自：智通财经 ...